Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma XenograftsGaspar J. Kitange, Jann N. Sarkaria, Ann C. Mladek et al.|Clinical Cancer Research|2012Cited by 151
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelGaspar J. Kitange, Jann N. Sarkaria, Brett L. Carlson et al.|Journal of Neuro-Oncology|2008Cited by 97
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft linesMichelle J. Clarke, Jann N. Sarkaria, Brett L. Carlson et al.|Molecular Cancer Therapeutics|2009Cited by 94
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastomaBianca M. Marin, Jann N. Sarkaria, Kendra A. Porath et al.|Neuro-Oncology|2021Cited by 81
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastomaElizabeth C. Randall, Nathalie Y.R. Agar, Kristina B. Emdal et al.|Nature Communications|2018Cited by 79